Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.

Tumati S, Largent-Milnes TM, Keresztes AI, Yamamoto T, Vanderah TW, Roeske WR, Hruby VJ, Varga EV.

Eur J Pharmacol. 2012 Jun 5;684(1-3):64-70.

2.

Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.

Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW, Varga EV.

J Neuroimmunol. 2012 Mar;244(1-2):23-31. doi: 10.1016/j.jneuroim.2011.12.021. Epub 2012 Jan 30.

3.

Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats.

Tumati S, Roeske WR, Largent-Milnes TM, Vanderah TW, Varga EV.

J Neurosci Methods. 2011 Jul 15;199(1):62-8. doi: 10.1016/j.jneumeth.2011.04.036. Epub 2011 May 6.

4.

Sustained morphine treatment augments prostaglandin E2-evoked calcitonin gene-related peptide release from primary sensory neurons in a PKA-dependent manner.

Tumati S, Roeske WR, Vanderah TW, Varga EV.

Eur J Pharmacol. 2010 Dec 1;648(1-3):95-101. doi: 10.1016/j.ejphar.2010.08.042. Epub 2010 Sep 15.

5.

Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA.

Tumati S, Roeske WR, Largent-Milnes T, Wang R, Vanderah TW, Varga EV.

Br J Pharmacol. 2010 Sep;161(1):51-64. doi: 10.1111/j.1476-5381.2010.00869.x.

6.

Functional selectivity in cannabinoid signaling.

Varga EV, Georgieva T, Tumati S, Alves I, Salamon Z, Tollin G, Yamamura HI, Roeske WR.

Curr Mol Pharmacol. 2008 Nov;1(3):273-84. Review.

PMID:
20021440
7.

Sustained morphine treatment augments capsaicin-evoked calcitonin gene-related peptide release from primary sensory neurons in a protein kinase A- and Raf-1-dependent manner.

Tumati S, Yamamura HI, Vanderah TW, Roeske WR, Varga EV.

J Pharmacol Exp Ther. 2009 Sep;330(3):810-7. doi: 10.1124/jpet.109.151704. Epub 2009 Jun 2.

8.

Sustained cannabinoid agonist treatment augments CGRP release in a PKA-dependent manner.

Tumati S, Yamamura HI, St John PA, Vanderah TW, Roeske WR, Varga EV.

Neuroreport. 2009 May 27;20(8):815-9. doi: 10.1097/WNR.0b013e32832be50b.

PMID:
19387418
9.

Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia.

Tumati S, Milnes TL, Yamamura HI, Vanderah TW, Roeske WR, Varga EV.

Eur J Pharmacol. 2008 Dec 28;601(1-3):207-8. doi: 10.1016/j.ejphar.2008.10.033. Epub 2008 Oct 21.

10.

Sustained morphine treatment augments basal CGRP release from cultured primary sensory neurons in a Raf-1 dependent manner.

Yue X, Tumati S, Navratilova E, Strop D, St John PA, Vanderah TW, Roeske WR, Yamamura HI, Varga EV.

Eur J Pharmacol. 2008 Apr 28;584(2-3):272-7. doi: 10.1016/j.ejphar.2008.02.013. Epub 2008 Feb 14.

11.

Quantitative evaluation of human delta opioid receptor desensitization using the operational model of drug action.

Navratilova E, Waite S, Stropova D, Eaton MC, Alves ID, Hruby VJ, Roeske WR, Yamamura HI, Varga EV.

Mol Pharmacol. 2007 May;71(5):1416-26. Epub 2007 Feb 22.

PMID:
17322005
12.
13.

Chronic morphine-mediated adenylyl cyclase superactivation is attenuated by the Raf-1 inhibitor, GW5074.

Yue X, Varga EV, Stropova D, Vanderah TW, Yamamura HI, Roeske WR.

Eur J Pharmacol. 2006 Jul 1;540(1-3):57-9. Epub 2006 May 3.

PMID:
16750187
14.

Morphine promotes phosphorylation of the human delta-opioid receptor at serine 363.

Navratilova E, Eaton MC, Stropova D, Varga EV, Vanderah TW, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2005 Sep 20;519(3):212-4.

PMID:
16135360
15.

Antinociception depends on the presence of G protein gamma2-subunits in brain.

Varga EV, Hosohata K, Borys D, Navratilova E, Nylen A, Vanderah TW, Porreca F, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2005 Jan 31;508(1-3):93-8. Epub 2005 Jan 12.

PMID:
15680258
16.

Agonist-specific regulation of the delta-opioid receptor.

Varga EV, Navratilova E, Stropova D, Jambrosic J, Roeske WR, Yamamura HI.

Life Sci. 2004 Dec 24;76(6):599-612. Review.

PMID:
15567186
17.

Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors.

Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, Fleishman DI, Engelhardt NV, Duncan SA.

Hepatology. 2004 Apr;39(4):1038-47.

PMID:
15057908
18.

Mutation S363A in the human delta-opioid receptor selectively reduces down-regulation by a peptide agonist.

Navratilova E, Varga EV, Stropova D, Jambrosic JC, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2004 Feb 6;485(1-3):341-3.

PMID:
14757159
19.

Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment.

Varga EV, Yamamura HI, Rubenzik MK, Stropova D, Navratilova E, Roeske WR.

Life Sci. 2003 Dec 5;74(2-3):299-311. Review.

PMID:
14607258
20.
21.

Converging protein kinase pathways mediate adenylyl cyclase superactivation upon chronic delta-opioid agonist treatment.

Varga EV, Rubenzik MK, Stropova D, Sugiyama M, Grife V, Hruby VJ, Rice KC, Roeske WR, Yamamura HI.

J Pharmacol Exp Ther. 2003 Jul;306(1):109-15. Epub 2003 Mar 26.

PMID:
12660310
22.

(2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.

Hosohata K, Varga EV, Alfaro-Lopez J, Tang X, Vanderah TW, Porreca F, Hruby VJ, Roeske WR, Yamamura HI.

J Pharmacol Exp Ther. 2003 Feb;304(2):683-8.

PMID:
12538822
23.

Agonist-specific down-regulation of the human delta-opioid receptor.

Okura T, Varga EV, Hosohata Y, Navratilova E, Cowell SM, Rice K, Nagase H, Hruby VJ, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2003 Jan 10;459(1):9-16.

PMID:
12505529
24.

Involvement of Raf-1 in chronic delta-opioid receptor agonist-mediated adenylyl cyclase superactivation.

Varga EV, Rubenzik M, Grife V, Sugiyama M, Stropova D, Roeske WR, Yamamura HI.

Eur J Pharmacol. 2002 Sep 6;451(1):101-2.

PMID:
12223234
25.

[Suppression of alpha-fetoprotein gene expression in somatic hybrids of AFP-positive and AFP-negative clones of rat hepatoma].

Kustova IF, Varga EV, Eraĭzer TL, Lazarevich NL.

Genetika. 2001 Oct;37(10):1330-9. Russian.

PMID:
11761608
26.

[Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].

Kokhanenko NIu, Ignashov AM, Varga EV, Polkanova MS, Aleshina LA, Kimbarovskaia AA, Osipenko SK, Lebedev EG.

Vopr Onkol. 2001;47(3):294-7. Russian.

PMID:
11544826
27.

[Expression of tissue-specific genes with progression of mouse hepatocellular carcinoma].

Varga EV, Cheremnova OA, Ovchinnikov DA, Shapiguzov AIu, Kudriavtseva EI, Morozova OV, Engel'gardt NV, Lazarevich NL.

Genetika. 2001 Jun;37(6):803-10. Russian.

PMID:
11517767
28.

Mutation W284L of the human delta opioid receptor reveals agonist specific receptor conformations for G protein activation.

Hosohata Y, Varga EV, Stropova D, Li X, Knapp RJ, Hruby VJ, Rice KC, Nagase H, Roeske WR, Yamamura HI.

Life Sci. 2001 Apr 6;68(19-20):2233-42.

PMID:
11358332
29.

Coupling of human delta-opioid receptor to retinal rod transducin in Chinese hamster ovary cells.

Varga EV, Stropova D, Kim T, Wang M, Roeske WR, Yamamura HI.

J Pharmacol Exp Ther. 2000 Jan;292(1):209-14.

PMID:
10604950
30.

[Expression of alpha-fetoprotein and hepatocyte nuclear factors in rat hepatoma clones: effect of retinoic acid].

Varga EV, Kustova IF, Lazarevich NL.

Mol Biol (Mosk). 1999 Mar-Apr;33(2):273-81. Russian. No abstract available.

PMID:
10377574
31.

Phosphorylation of adenylyl cyclase VI upon chronic delta-opioid receptor stimulation.

Varga EV, Stropova D, Rubenzik M, Waite S, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1999 Jan 8;364(2-3):R1-3.

PMID:
9932732
32.

Identification of adenylyl cyclase isoenzymes in CHO and B82 cells.

Varga EV, Stropova D, Rubenzik M, Wang M, Landsman RS, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1998 May 8;348(2-3):R1-2.

PMID:
9652350
33.

Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line.

Kovacs I, Yamamura HI, Waite SL, Varga EV, Roeske WR.

J Pharmacol Exp Ther. 1998 Feb;284(2):500-7.

PMID:
9454790
34.

The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.

Varga EV, Li X, Stropova D, Zalewska T, Landsman RS, Knapp RJ, Malatynska E, Kawai K, Mizusura A, Nagase H, Calderon SN, Rice K, Hruby VJ, Roeske WR, Yamamura HI.

Mol Pharmacol. 1996 Dec;50(6):1619-24. Erratum in: Mol Pharmacol 1997 Aug;52(2):335.

PMID:
8967985
35.

delta-Opioid receptor: the third extracellular loop determines naltrindole selectivity.

Li X, Varga EV, Stropova D, Zalewska T, Malatynska E, Knapp RJ, Roeske WR, Yamamura HI.

Eur J Pharmacol. 1996 Apr 4;300(1-2):R1-2.

PMID:
8741185
36.

Identification of a human delta opioid receptor: cloning and expression.

Knapp RJ, Malatynska E, Fang L, Li X, Babin E, Nguyen M, Santoro G, Varga EV, Hruby VJ, Roeske WR, et al.

Life Sci. 1994;54(25):PL463-9.

PMID:
8201839

Supplemental Content

Loading ...
Support Center